Abstracts - faqs.org

Abstracts

Business

Search abstracts:
Abstracts » Business

A sugar switch for anti-inflammatory antibodies

Article Abstract:

A study suggests that addition of sialic acid to the oligosaccharides on human immunoglobulin G (IgG) molecules enhances their anti-inflammatory activity but might compromise their cytotoxicity, as evidenced in mice by reduced platelet depletion by platelet-specific recombinant monoclonal antibodies (rMAbs). X-ray crystallography reveals multiple noncovalent interactions between the oligosaccharide and the protein, implying that both influence antibody conformation.

Author: Jefferis, Roy
Publisher: Nature Publishing Co.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2006
Care and treatment, Autoimmune diseases, Monoclonal antibodies, Sialic acids, Structure

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Post-translational modifications in the context of therapeutic proteins

Article Abstract:

An overview of the range of post-translational modifications (PTMs) associated with natural and recombinant therapeutic proteins is presented and the way such modifications might influence the properties of protein drug candidates is discussed. A better understanding of such structural-functional relationships would facilitate the development of second-generation products displaying a PTM profile engineered to optimize therapeutic usefulness.

Author: Walsh, Gary, Jefferis, Roy
Publisher: Nature Publishing Co.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2006
Methods, Analysis, Glycosylation, Protein research, Post-translational modification

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Biopharmaceutical benchmarks 2006

Article Abstract:

An update on biopharmaceuticals approved during the past three and a half years (from January 2003 to June 2006), examining which types of biopharmaceuticals are launched and for what indications is presented. Overall, some 165 biopharmaceutical products have gained approval, with a market size estimated at some $33 million in 2004 and projected to reach $70 billion by the end of the decade.

Author: Walsh, Gary
Publisher: Nature Publishing Co.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2006
Product information, Government regulation, Licensing, certification and accreditation

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Research, United States, Biopharmaceutics, Biopharmaceuticals
Similar abstracts:
  • Abstracts: A passion for collaboration from the get-go: Merk and Co., Inc. and Bioxell show how big pharma and small biotechs can make perfect partners
  • Abstracts: Modeling cellular machinery through biological network comparison. Exploiting biological complexity for strain improvement through systems biology
  • Abstracts: A liposome-PCR assay for the ultrasensitive detection of biological toxins. Targeted antigen delivery to antigen: presenting cells including dendritic cells by engineered Fas-mediated apoptosis
  • Abstracts: DNA patenting: The end of an era? Trust, patents and public perceptions: the governance of controversial biotechnology research
  • Abstracts: Learning the language. Good ideas gone bad. Writer's lock
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.